[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:mitogen-activated-protein-kinase-kinase":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Mitogen-Activated Protein Kinase Kinase",3,2,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07318324","Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:17:46.653867Z","2026-07-05T05:32:16.676290Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05111561","Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced\u002FMetastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer",[12],"2026-08-26T02:17:47.813245Z","2026-07-24T01:27:14.906567Z",{"nct_id":23,"title":24,"phases":25,"status":27,"updated_at":28,"content_modified":29},"NCT05554328","Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial",[26],"Phase 2","ACTIVE_NOT_RECRUITING","2026-08-03T03:36:04.680662Z","2026-05-05T02:43:27.963217Z"]